| abstract |
The present invention is based on the discovery that inactivation of the CB1 receptor reduces liver fibrosis associated with liver damage and liver disease, for the treatment of liver disease, preferably liver disease leading to liver fibrosis. It aims to provide various methods and compositions. For this reason, the present invention relates to the use of an antagonist of the CB1 receptor for preparing a composition for treating liver disease, more preferably N-piperidino-5- (4-chlorophenyl) -1- (2,4- Dichlorophenyl) -4-methylpyrazole-3-carboxamide is used. [Selection] Figure 1 |